share_log

Allmed Medical ProductsLtd's (SZSE:002950) Weak Earnings May Only Reveal A Part Of The Whole Picture

Allmed Medical ProductsLtd's (SZSE:002950) Weak Earnings May Only Reveal A Part Of The Whole Picture

奧美醫療產品有限公司(SZSE:002950)的盈利疲軟只可能揭示整個局面的一部分
Simply Wall St ·  09/06 18:41

Allmed Medical Products Co.,Ltd's (SZSE:002950) stock showed strength, with investors undeterred by its weak earnings report. We think that shareholders might be missing some concerning factors that our analysis found.

奧美醫療有限公司(SZSE:002950)的股票表現強勁,投資者對其疲弱的收益報告並不擔心。我們認爲股東可能忽略了我們分析發現的一些令人擔憂的因素。

big
SZSE:002950 Earnings and Revenue History September 6th 2024
SZSE:002950盈利和營業收入歷史數據2024年9月6日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Allmed Medical ProductsLtd's profit received a boost of CN¥35m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. If Allmed Medical ProductsLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據顯示,在過去一年裏,奧美醫療有限公司的利潤得到了3500萬人民幣的非正常項目的推動。我們不得不承認,更高的利潤通常讓我們感到樂觀,但如果利潤能夠持續增長的話,我們會更加歡迎。當我們對成千上萬家上市公司進行數據分析時,我們發現,一個給定年度的非正常項目的增長通常在下一年不會重複出現。這是可以預料的,因爲這些提升被描述爲「非正常」。如果奧美醫療有限公司沒有看到該貢獻的重複,那麼其他條件不變,我們預計其利潤將在當前年度下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Allmed Medical ProductsLtd.

注:我們始終建議投資者檢查資產負債表強度。點擊此處查看我們對奧美醫療有限公司的資產負債表分析。

Our Take On Allmed Medical ProductsLtd's Profit Performance

我們對奧美醫療有限公司的利潤表現的看法

We'd posit that Allmed Medical ProductsLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Allmed Medical ProductsLtd's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Allmed Medical ProductsLtd at this point in time. When we did our research, we found 3 warning signs for Allmed Medical ProductsLtd (1 is concerning!) that we believe deserve your full attention.

我們認爲奧美醫療產品有限公司的法定盈利並不能完全反映持續的生產力,因爲存在較大的非常項目。因此,我們認爲奧美醫療產品有限公司的法定利潤可能比其基本盈利能力更好。可惜,它的每股收益在過去的十二個月中有所下降。本文的目標是評估我們能否依靠法定盈利來反映該公司的潛力,但還有很多需要考慮的因素。所以,儘管盈利質量很重要,但同樣重要的是考慮當前時點奧美醫療產品有限公司面臨的風險。在我們的研究中,我們發現了3個關於奧美醫療產品有限公司的警示信號(其中1個令人擔憂!),我們認爲這值得您充分關注。

This note has only looked at a single factor that sheds light on the nature of Allmed Medical ProductsLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

本文僅僅從一個因素考慮了奧美醫療產品有限公司利潤的性質。但還有很多其他方法可以解讀一家公司。有些人認爲股本回報率較高是一家優質企業的良好跡象。雖然這可能需要您進行一些調研,但您可能會發現這個免費的高股本回報率公司集合或這個持有大量內部股份的股票列表對您有幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論